Combination chemotherapy with or without s.c. IL-2 and IFN-α: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)

J Atzpodien*1,2,4, K Neuber3, D Kamanabrou4, M Fluck1, EB Bröcker5, C Neumann4, TM Rünger7, G Schuler8, P von den Driesch9, I Müller9, E Paul1, T Patzelt1 and M Reitz1

1 European Institute for Tumor Immunology and Prevention (EUTIP), Gotenstr. 152, 53175 Bonn, Germany; 2 Medizinische Hochschule Hannover, Germany; 3 Universitätsklinikum Hamburg, Germany; 4 Fachklinik Hornheide an der Universität Münster, Germany; 5 Universitätsklinikum Würzburg, Germany; 6 Universitätsklinik Göttingen, Germany; 7 Boston University School of Medicine, USA; 8 Universitätsklinikum Erlangen, Germany; 9 Klinikum Nürnberg-Nord, Germany

The purpose of this randomized trial was to evaluate the efficacy of combination chemoimmunotherapy compared with chemotherapy alone. A total of 124 patients were randomized to receive intravenous cisplatin (35 mg m⁻², days 1–3), carmustine (150 mg m⁻², day 1, cycles 1 and 3 only), dacarbazine (220 mg m⁻², days 1–3) and oral tamoxifen (20 mg m⁻², daily) in combination with (n=64) or without (n=60) sequential subcutaneous IL-2 and IFN-α. In those patients who received sequential immunotherapy, each cycle of chemotherapy was followed by outpatient s.c. IL-2 (10×10⁶ IU m⁻², days 3–5, week 4; 5x10⁶ IU m⁻², days 1, 3, 5, week 5) and s.c. IFN-α (5x10⁶ IU m⁻², day 1, week 4; days 1, 3, 5, week 5). The overall response rate of patients treated with the combination of chemotherapy and IL-2/IFN-α was 34.3% with seven complete responses (10.9%) and 15 partial responses (23.4%). In patients treated with chemotherapy, only, the overall response rate was 29.9% with eight complete responses (13.3%) and 10 partial responses (16.6%). There was no significant difference in median progression free survival (0 months vs 4 months) and in median overall survival (12 months vs 13 months) for combined chemoimmunotherapy and for chemotherapy, respectively.

British Journal of Cancer (2002) 86, 179 – 184. DOI: 10.1038/sj/bjc/6600043 www.bjcancer.com © 2002 The Cancer Research Campaign

Keywords: melanoma; interleukin-2; interferon alpha; chemotherapy

Metastatic melanoma responds poorly to the currently available chemotherapeutic agents and, until today, no standard treatment has been established. Most single agent chemotherapeutics provide only low response rates. Dacarbazine (DTIC), the most active single agent in the treatment of melanoma, can be expected to yield a response rate of about 20% (McClay and McClay, 1996). Even though most trials of combination chemotherapy for the treatment of metastatic melanoma clearly have not been superior to DTIC alone, the combination of carmustine (BCNU), DTIC, cisplatin, and tamoxifen has produced significant antitumour responses in up to 50% of patients (McClay and McClay, 1994; Middleton et al, 2000; Richards et al, 1992). A further increase in the rate of objective responses may be achieved by introducing cytokines into the therapeutic regimens, with interleukin-2 (IL-2) and interferon alpha (IFN-α) being the most widely acclaimed. Monotherapy with IL-2 results in up to 29% objective responses (Rosenberg et al, 1994). Different types of interferons have also been intensively explored (Creagan et al, 1990). While a defined subgroup of patients has responded, response rates with immunochemotherapies have been lower than with the best chemotherapy regimens, however, sustained responses have been consistently observed following IL-2 based chemoimmunotherapy.

Recently, several trials have investigated the combination of various cytotoxic agents with IL-2 and IFN-α. While primarily in phase II studies several authors claimed a clear advantage of this chemoimmunotherapy over chemotherapy alone (Legha et al, 1996; Richards et al, 1992), more recently randomized trials raised doubts about the effectiveness and benefit of this combination (Johnston et al, 1998; Rosenberg et al, 1999).

We have performed a prospective randomized trial in patients with metastatic melanoma treated either with a chemotherapy regimen of cisplatin, carmustine, dacarbazine, and tamoxifen, or with the identical chemotherapy followed by outpatient s.c. IL-2 and s.c. IFN-α.

PATIENTS AND METHODS

Patients

Between May 1995 and May 1999, 124 patients were randomized and considered evaluable for response (Table 1). Forty-one females and 83 males were treated either with combined chemoimmuno-
Clinical blood cell count

British Journal of Cancer (2002) 86

TABLE 1 Patients’ characteristics

| Characteristics     | Therapy* |
|---------------------|----------|
| Entered             | Arm A    | Arm B    | All       |
| Sex                 | 64       | 60       | 124       |
| Age                 | 46       | 37       | 83        |
| Age                 | 18       | 23       | 41        |
| Age                 | 57       | 57       | 57        |
| Range               | 28–72    | 29–77    | 28–77     |
| Histology           |          |          |           |
| Cutaneous           |          |          |           |
| Nodular             | 13       | 18       | 31        |
| Amelanotic          | 1        | 0        | 1         |
| Superficial spreading | 18     | 14       | 32        |
| Acral lentignous    | 3        | 2        | 5         |
| Uveal               | 6        | 5        | 11        |
| Unknown             | 14       | 13       | 27        |
| Pretreatment        |          |          |           |
| Surgery             | 53       | 54       | 107       |
| Local radiation     | 6        | 10       | 16        |
| Chemotherapy        | 4        | 3        | 7         |
| Immunotherapy;      | 5        | 6        | 11        |
| Chemotherapy/immunotherapy | 2       | 2        | 4         |
| Others              | 1        | 4        | 5         |

*Arm A (i.v. DTIC, i.v. cisplatin, i.v. BCNU, p.o. tamoxifen, s.c. IL-2, s.c. IFN-α); Arm B (i.v. DTIC, i.v. cisplatin, i.v. BCNU, p.o. tamoxifen).

or chemotherapy alone. Median follow-up of these patients was 12 months (range 0–62 months). Ninety-seven patients had not been treated with systemic therapy before, 27 patients had received previous systemic immuno- or chemotherapy treatment.

Criteria for entry into the study were: histologically confirmed metastatic melanoma; Karnofsky performance status >80%; white blood cell count >3500 μl⁻¹; platelet count >100 000 μl⁻¹; haematocrit >30%; serum creatinin and bilirubin <1.5 of the upper normal limit; age between 18 and 75 years and a life expectancy of >3 months.

This study was approved by the institutional review board of the Medizinische Hochschule Hannover and by participating centres; written informed consent was obtained from all patients prior to entry into the study.

Study design

All patients received a chemotherapy regimen comprising cisplatin (35 mg m⁻², i.v., days 1–3), carmustine (150 mg m⁻², i.v., day 1, cycles 1 and 3 only), dacarbazine (220 mg m⁻², i.v., days 1–3) and oral tamoxifen (20 mg m⁻², daily) in combination with (n=64) or without (n=60) subcutaneous IL-2 and IFN-α. In those patients, who were randomized to receive chemoimmunotherapy, each cycle of chemotherapy was followed by outpatient immuno-therapy with combined IL-2 (10×10⁶ IU m⁻², days 3–5, week 4; 5×10⁶ IU m⁻², days 1, 3, 5, week 5) and IFN-α (5×10⁶ IU m⁻², day 1, weeks 4; days 1, 3, 5, week 5); randomization was performed centrally. Five week treatment cycles were repeated unless progression of disease occurred. Re-evaluation of the patients’ tumour status was performed between treatment cycles. Patients received an average of 2.7 (Arm A, median 2.0; range 1–5) and 1.9 (Arm B, median 2.0; range 0–4) treatment cycles.

Assessment of response

Response to therapy was evaluated according to World Health Organization (WHO) criteria with regular re-evaluation intervals every 8 weeks; all repeated scans were reported to the data center:

- complete response — disappearance of all signs of disease for a minimum of 8 weeks; partial response — 50% or more reduction in the sum of products of the greatest perpendicular diameters of measurable lesions, no increase in lesion size and no new lesions; stable disease — less than a partial response with no disease progression for at least 8 weeks; progressive disease — 25% or more increase in sum of products in the longest perpendicular diameters of measurable lesions or the development of new lesions. Duration of response was measured from the initial date of response. Two patients were randomized, but did not receive therapy and were evaluated as progressive disease patients. Treatment efficacy was assessed on intent-to-treat basis.

Statistical analysis

Survival was measured from start of therapy to date of death or to the last known date to be alive. The statistical end points in our analysis were (1) objective response and (2) overall and progression free survival of patients. The progression free survival after 1 year was assumed to be 40% (chemoimmunotherapy) and 20% (chemotherapy), respectively. The intention was to find a chemoimmunotherapy induced progression free survival benefit over chemotherapy alone at 20% with a probability of 95% (≥0.05) and a sample power of 1–ß=0.80. Based on this assumption an intended patient accrual of 64 patients per therapy arm was required in case of a statistically significant survival benefit after combined chemoimmunotherapy. The probability of overall survival was plotted over time according to the method of Kaplan and Meier. Statistical significance was assessed using the Log Rank, Tarone Ware and the Breslow test; SPSS software was employed.

RESULTS

A total of 124 patients were enrolled in this clinical trial and randomized to receive combined chemoimmunotherapy (n=64) or chemotherapy alone (n=60) (Table 1). Patient evaluation was performed according to the guidelines described above.

Response to therapy was evaluated according to World Health Organization (WHO) criteria with regular re-evaluation intervals every 8 weeks.

Treatment response

Seven patients (10.9%) treated with chemoimmunotherapy achieved a complete response and 15 patients (23.4%) had a partial remission (Table 2). The overall objective response rate of combined chemoimmunotherapy was 34.3% (median survival 29 months).

Table 2 Sites of disease and response of patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with IL-2 and IFN-α

| Tumour site* | CR | PR | SD | PD | Total |
|--------------|----|----|----|----|-------|
| Lymph nodes  | 5  | 7  | 5  | 21 | 38    |
| Liver        | 1  | 9  | 4  | 22 | 36    |
| Lung         | 1  | 8  | 3  | 15 | 27    |
| Spleen       | 1  | 1  | 1  | 6  | 6     |
| Skin/subcutaneous | 3  | 1  | 0  | 6  | 10    |
| Brain        | 0  | 0  | 0  | 1  | 1     |
| Bone         | 0  | 1  | 0  | 3  | 4     |
| Adrenal      | 0  | 2  | 1  | 2  | 5     |
| Spleen       | 0  | 2  | 0  | 4  | 6     |
| Other        | 0  | 0  | 1  | 6  | 7     |
| Total        | 7  | 15 | 9  | 33 | 64    |

Abbreviations: CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease. *Patients may have had more than one site.
months; 95% CI, 9, 49) with a median duration of response of 9 months (range 5–62 months). While in complete responders, the median response duration was 25 months (range 5–62 months), the median duration of partial responses was 7 months (range 5–19 months). Objective tumour regressions were seen in lymph nodes (12), liver (10), lung (9), skin (4), bone (1), adrenal (2) and spleen (2). Nine patients (14.1%) showed disease stabilization and 33 patients (51.6%) exhibited continuous disease progression despite therapy.

In the chemotherapy group the overall objective response rate was 29.9% (median survival 24 months; 95% CI, 16, 32) with eight patients (13.3%) achieving a complete response and 10 patients (16.6%) a partial remission (Table 3). The median duration of response ranged from 5 to 47 months (CR, PR, median 15 months). While in complete responders, the median duration of response ranged from 5 to 47 months (median 28 months), the median duration of response in partial responders ranged from 5 to 34 months (median 7 months), respectively. Objective tumour regressions were seen in lymph nodes (14), liver (3), lung (9), skin (4) and adrenal (1). Fourteen patients (23.3%) showed disease stabilization. In 28 patients (46.7%) progression of disease occurred.

### Overall survival

Overall median survival of all patients entered into the study was 13 months (95% CI 10; 16). There was no significant difference in median overall survival for combined chemoimmunotherapy (12 months) and for chemotherapy (13 months), respectively (Figure 1). Patients’ sex had also no influence on median survival (data not shown). Twenty-five patients are alive at a median follow-up of 24 months (range 2–62 months). Two patients continue to be alive after more than 5 years from chemoimmunotherapy. A 3-year survival of 12.96% and 11.42% was achieved with combined chemoimmunotherapy and with chemotherapy alone, respectively. For complete responders, median survival has not been reached at 62 months (range 20–62 months). In contrast, partial responders and patients with disease stabilization had both a median survival of 16 months (range 5–40 months and 2–38 months) as opposed to a median survival of 8 months (range 0–40 months) in progressive disease patients (Figure 2).

In the chemoimmunotherapy group, median overall survival of objective responses was 29 months (range 5–62 months, 95% CI 9, 49), while in the chemotherapy group a median survival of 24 months (range 8–47 months, 95% CI 16, 32) was achieved (data not shown).

There was a significant ($P < 0.0001$) difference in overall survival for all patients with liver metastases with a median survival of 9 months (chemoimmunotherapy) and 8 months (chemotherapy) as opposed to patients without liver metastases with a median survival of 20 months (chemoimmunotherapy) and 17 months (chemotherapy), respectively (Figure 3).

### Progression free survival

The progression free survival ranged from 0 to 62 (median 4 months) for all patients entered into the study. There was no significant difference in median progression free survival between patients treated with chemoimmunotherapy (0 months, range 0–62 months) or with chemotherapy (4 months, range 0–47 months) (Figure 4).

The median progression free survival for patients with liver metastases was 0 months independent of the treatment regimen as compared to a median progression free survival of 7 months (range 0–62 months, chemoimmunotherapy) and 5 months (range 0–47 months, chemotherapy) in patients without liver metastases (data not shown).

### Treatment toxicity

Chemotherapy led to significant haematotoxicity with WHO grade IV thrombocytopenia in 25% and leukopenia in approximately 26% of treatment cycles, respectively. Immunotherapy related side effects included WHO grade III and IV malaise in 21%, anorexia in 21%, chills in 8%, diarrhea in 5% and fevers in less than 25% of treatment cycles, respectively (data not shown).

Overall, no life threatening toxicities were observed, and no toxic deaths occurred. Generally, immunotherapy could be administered in the outpatient setting. Chemotherapy required inpatient stays of 4 days per cycle.

### DISCUSSION

In the present prospective randomized trial we reported the results of 124 patients with progressive metastatic melanoma who received a combined chemoimmunotherapy (IFN-, IL-2 combined with DTIC, cisplatin, BCNU, and tamoxifen) or a chemotherapy (DTIC, cisplatin, BCNU, and tamoxifen) alone. We observed an overall objective response in 34.3% of patients treated with the combined chemoimmunotherapy which is comparable with earlier trials achieving response rates between 23% to 64% (Atkins et al, 1994; Atzpodien et al, 1995; Fein et al, 1995; Hoffmann et al, 1998; Johnston et al, 1998; Legha, 1998; Middleton et al, 2000; Pyrhonen et al, 1992; Rosenberg et al, 1999; Thompson et al, 1997). Whereas in previous clinical trials, introducing cytokines in chemotherapeutic regimens yielded an enhanced efficacy (Atkins et al, 1994; Legha et al, 1996), our results raise doubts concerning the potential benefits of the presently used dosages of IL-2 and INF-α for therapy of metastatic melanoma since objective response rates of patients treated with chemotherapy alone were similar (29.9%) to sequential chemoimmunotherapy (34.3%).

In addition, in our trials no significant difference in survival time was observed for patients treated with chemoimmunotherapy (median 12 months) and chemotherapy (median 13 months), respectively, which is also supported by recent results of other cytokine based therapy regimens (Johnston et al, 1998; Rosenberg et al, 1999). Although overall survival of objective responses was slightly increased in the chemoimmunotherapy group (median 29 months, 95% CI 9, 49) than in the chemotherapy group (median 24 months, 95% CI 16, 32), the response duration of patients was shorter after chemoimmunotherapy (median 9 months) when compared to chemotherapy (15 months). In contrast, Legha et al (1997) reported a significantly increased proportion (10%) of long-term responders after chemoimmunotherapy.

---

**Table 3** Sites of disease and response of patients receiving DTIC, cisplatin, BCNU and tamoxifen.

| Tumour site | CR | PR | SD | PD | Total |
|-------------|----|----|----|----|-------|
| Lymph nodes | 5 | 9 | 8 | 17 | 39 |
| Liver | 1 | 2 | 4 | 19 | 26 |
| Lung | 4 | 5 | 8 | 17 | 34 |
| Local relapse | 1 | 2 | 2 | 2 | 7 |
| Skin/Subcutaneous | 1 | 3 | 4 | 12 | |
| Brain | 0 | 0 | 1 | 2 | 3 |
| Bone | 0 | 0 | 3 | 3 | 6 |
| Adrenal | 1 | 0 | 0 | 4 | 5 |
| Spleen | 0 | 0 | 1 | 4 | 5 |
| Other | 0 | 2 | 2 | 1 | 6 |
| Total | 8 | 10 | 14 | 28 | 60 |

Abbreviations: CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease. *Patients may have had more than one site.
Clinical

1.0
0.8
0.6
0.4
0.2
0.0
0 1 2 2 4 3 6 4 8 6 0 7 2
321x162
Months

Arm A vs Arm B
Log Rank P = 0.7904
Breslow P = 0.9313
Tarone P = 0.9697

Arm A
DTIC, Cisplatin, BCNU
n = 64 patients
Median = 12 months
3-year survival = 12.96%

Arm B
DTIC, Cisplatin
BCNU, Tamoxifen
n = 60 patients
Median = 13 months
3-year survival = 11.42%

No. of patients at risk
Arm A 64 32 17 8 4 2
Arm B 60 31 15 5 – –

Figure 1 Overall survival (Kaplan-Meier estimates) of 124 patients treated with chemoimmunotherapy (i.v. DTIC, i.v. cisplatin, i.v. BCNU, p.o. tamoxifen, s.c. interleukin-2 and s.c. interferon-α) or chemotherapy (i.v. DTIC, i.v. cisplatin, i.v. BCNU and p.o. tamoxifen) alone. Survival was measured from start of therapy.

CR
n = 15 patients
Median not reached
3-year survival = 60.67%

PR
n = 25 patients
Median = 16 months
3-year survival = 20.27%

SD
n = 23 patients
Median = 16 months
3-year survival = 8.85%

PD
n = 61 patients
Median = 8 months
3-year survival = 1.96%

No. of patients at risk
CR 15 15 13 8 4 2
PR 15 18 8 3 0 0
SD 23 11 6 2 – –
P D 61 20 6 2 – –

Figure 2 Overall survival (Kaplan-Meier estimates) of 124 patients classified by treatment response. CR=complete remission, PR=partial remission, SD=stable disease, PD=progressive disease. Survival was measured from start of therapy.
1 = Arm A, without liver metastases, DTIC, Cisplatin, BCNU, Tamoxifen, IL-2, IFN-α
\( n = 28 \) patients
Median = 20 months
3-year survival = 29.61%

2 = Arm B, without liver metastases, DTIC, Cisplatin, BCNU, Tamoxifen
\( n = 36 \) patients
Median = 17 months
3-year survival = 15.08%

3 = Arm A, with liver metastases, DTIC, Cisplatin, BCNU, Tamoxifen, IL-2, IFN-α
\( n = 36 \) patients
Median = 9 months
3-year survival = 7.9%

4 = Arm B, with liver metastases, DTIC, Cisplatin, BCNU, Tamoxifen
\( n = 26 \) patients
Median = 8 months
3-year survival = 4.8%

Figure 3 Overall survival (Kaplan-Meier estimates) of 124 patients classified by risk (liver metastases). Survival was measured from start of therapy.

Arm A vs Arm B
Log Rank \( P = 0.8245 \)
Breslow \( P = 0.8123 \)
Tarone \( P = 0.8447 \)

Figure 4 Progression free survival for all 124 patients treated with chemoimmunotherapy (i.v. DTIC, i.v. cisplatin, i.v. BCNU, p.o. tamoxifen, s.c. interleukin-2 and s.c. interferon-α) or chemotherapy (i.v. DTIC, i.v. cisplatin, i.v. BCNU and i.v. tamoxifen) alone. Plots were generated by the Kaplan-Meier method and progression free survival was measured from start of therapy.
The discrepancy in the effect of cytokines in metastatic melanoma therapies might be best explained by the following uncontrolled variables: (A) patient selection and clinical/biological risk; (B) variations in the rIL-2 based regimen (e.g., reconstitution of drug, route and dose of administration); and (C) different standards of patient care (e.g., supportive care upon IL-2 therapy). In fact, previous reports have repeatedly shown that overall survival is highly risk-dependent (Hoffmann et al., 1998; Rusthoven et al., 1996). This is confirmed by our study since we reported that patients with liver metastases had a significantly shorter survival and shorter progression free survival compared to patients without liver metastases. Notably, the proportion of patients with hepatic metastases varied between 56% (chemoimmunotherapy) and 43% (chemotherapy alone).

In summary, this prospectively randomized clinical trial showed no statistically significant benefit of IL-2, INF- based combined chemoimmunotherapy in patients with metastatic melanoma compared to chemotherapy alone. So far, also no standard was established confirming a significant survival benefit of polychemotherapy when compared to DTIC, alone (Chiarion Sileni et al., 2001).

REFERENCES

Atkins MB, O’Boyle KR, Sosman JA, Weiß GR, Margolin KA, Ernest ML, Kappler K, Mier JW, Sparano JA, Fischer RI (1994) Multinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 12: 1553 – 1567

Atzpodien J, Lopez Haminnen E, Kirchner H, Franzeck A, Körfer A, Volkenandt M, Duensing S, Schomburg A, Chaitchik S, Poliwoda H (1995) Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-α after intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer 31: 876 – 881

Chiarion Sileni V, Nortilli R, Aversa SM, Paccagnella A, Medici M, Corti I, Atkins MB, O’Boyle KR, Sosman JA, Weiß GR, Margolin KA, Ernest ML, Legha SS, Rusthoven et al. (1998), future clinical trials might focus on new combinations, different dosages and dose distribution regimens of IL-2 and INF- to increase both efficacy and tolerability for patients with metastatic melanoma.

ACKNOWLEDGEMENTS

The authors would like to thank Dr Susanne Schärd and Dr Eckhardt Kämpgen for support. J Atzpodien is supported by grants of the Deutsche Krebshilfe, Wilhelm Sander-Stiftung, and Gesellschaft zur Förderung immunologischer Krebstherapien e.V.

Legha SS, Ring S, Eton O, Bediakian A, Plager C, Papadopoulos N (1997) Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience. Cancer J Sci Am 3(1 Suppl): 9 – 15

McCay EF, McClay ME (1994) Tamoxifen: is useful in the treatment of patients with metastatic melanoma? J Clin Oncol 12: 617 – 626

McCay EF, McClay ME (1996) Systemic chemotherapy for the treatment of metastatic malignant melanoma. Semin Oncol 23: 744 – 753

Middleton MR, Lorigan P, Owen J, Asshcroft L, Lee SM, Harper P, Thatcher N (2000) A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 82: 1158 – 1162

Pyrhonen S, Hakka-Kemppinen M, Muñonen T (1992) A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 10: 1919 – 1926

Richards JM, Mehta N, Ramming K, Skosey P (1992) Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10: 1338 – 1343

Rosenberg JM, Yang JC, Topalian SL, Schaverienzuber DJ, Web JS, Parkinson DR, Seipp CA, Einhorn JH, White DE (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271: 907 – 913

Rusthoven JJ, Quirt JG, Issac NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HK, Veurma S, Armitage GR, Zee B, Bennett K (1996) Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14: 2083 – 2090

Stark JJ, Dillman RO, Schulof R, Wiemann MC, Barth NM, Honeyncutt PJ, Soori G (1998) Interferon alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study for the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program. Cancer 82: 1677 – 1681

Thompson JA, Gold PJ, Markowitz DR, Byrd DR, Lindgren CG, Fefer A (1997) Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma. Cancer J Sci Am 3(1 Suppl): 29 – 34

British Journal of Cancer (2002) 86(2), 179 – 184 © 2002 The Cancer Research Campaign